Michael Portelli
Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels
Portelli, Michael; Siedlinski, Mateusz; Stewart, Ceri E.; Postma, Dirkje S.; Nieuwenhuis, Maartje A.; Vonk, Judith M.; Nurnberg, Peter; Altmuller, Janine; Moffatt, M.F.; Wardlaw, Andrew J.; Parker, Stuart G.; Connolly, Martin J.; Koppelman, Gerard H.; Sayers, Ian
Authors
Mateusz Siedlinski
Ceri E. Stewart
Dirkje S. Postma
Maartje A. Nieuwenhuis
Judith M. Vonk
Peter Nurnberg
Janine Altmuller
M.F. Moffatt
Andrew J. Wardlaw
Stuart G. Parker
Martin J. Connolly
Gerard H. Koppelman
Professor IAN SAYERS ian.sayers@nottingham.ac.uk
PROFESSOR OF RESPIRATORY MOLECULAR GENETICS
Abstract
The soluble cleaved urokinase plasminogen activator receptor (scuPAR) is a circulating protein detected in multiple diseases, including various cancers, cardiovascular disease, and kidney disease, where elevated levels of scuPAR have been associated with worsening prognosis and increased disease aggressiveness. We aimed to identify novel genetic and biomolecular mechanisms regulating scuPAR levels. Elevated serum scuPAR levels were identified in asthma (n=514) and chronic obstructive pulmonary disease (COPD; n=219) cohorts when compared to controls (n=96). In these cohorts, a genome-wide association study of serum scuPAR levels identified a human plasma kallikrein gene (KLKB1) promoter polymorphism (rs4253238) associated with serum scuPAR levels in a control/asthma population (P=1.17×10−7), which was also observed in a COPD population (combined P=5.04×10−12). Using a fluorescent assay, we demonstrated that serum KLKB1 enzymatic activity was driven by rs4253238 and is inverse to scuPAR levels. Biochemical analysis identified that KLKB1 cleaves scuPAR and negates scuPAR's effects on primary human bronchial epithelial cells (HBECs) in vitro. Chymotrypsin was used as a proproteolytic control, while basal HBECs were used as a control to define scuPAR-driven effects. In summary, we reveal a novel post-translational regulatory mechanism for scuPAR using a hypothesis-free approach with implications for multiple human diseases.
Citation
Portelli, M., Siedlinski, M., Stewart, C. E., Postma, D. S., Nieuwenhuis, M. A., Vonk, J. M., Nurnberg, P., Altmuller, J., Moffatt, M., Wardlaw, A. J., Parker, S. G., Connolly, M. J., Koppelman, G. H., & Sayers, I. (2013). Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB Journal, 28(2), https://doi.org/10.1096/fj.13-240879
Journal Article Type | Article |
---|---|
Publication Date | Nov 18, 2013 |
Deposit Date | May 30, 2014 |
Publicly Available Date | May 30, 2014 |
Journal | FASEB Journal |
Print ISSN | 0892-6638 |
Electronic ISSN | 1530-6860 |
Publisher | Federation of American Society of Experimental Biology (FASEB) |
Peer Reviewed | Peer Reviewed |
Volume | 28 |
Issue | 2 |
DOI | https://doi.org/10.1096/fj.13-240879 |
Keywords | GWAS, Proteolysis, Respiratory disease, HBECs, Cellular proliferation and wound repair |
Public URL | https://nottingham-repository.worktribe.com/output/997117 |
Publisher URL | http://www.fasebj.org/content/28/2/923.abstract |
Contract Date | May 30, 2014 |
Files
Portelli_Genome-wide_protein_QTL_mapping_identifies_human.pdf
(543 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/3.0/
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search